publication date: Jul. 2, 2020
NCI Trials
NCI Trials for July 2020
The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10327
A Phase I Trial of MLN0128 (Sapanisertib) and CB-839 HCL (Telaglenastat) in Advanced NSCLC Patients
City of Hope Comprehensive Cancer Center LAO
Riess, Jonathan W.
(916) 734-3772
Phase I – 10335
A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
Yale University Cancer Center LAO
Ratner, Lee
(314) 362-8836
Phase I – 10349
A Phase I Trial of the P97 Inhibitor CB-5339 in Patients with Advanced Solid Tumors and Lymphomas
National Cancer Institute LAO
Takebe, Naoko
(240) 781-3398
Phase I – 10388
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Ohio State University Comprehensive Cancer Center LAO
Chauhan, Aman
(504) 278-0134
Phase II – 10211
A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Yale University Cancer Center LAO
Berlin, Jordan D.
(615) 343-4128
Phase II – APEC1621N
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LOXO-292 in Patients with Tumors Harboring RET Gene Alterations
Children’s Oncology Group
Continue reading NCI Trials for July 2020
To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
